InvVax is harnessing the human adaptive immune system to fight global infectious disease including pandemic influenza.
InvVax has raised $256K in total funding. The most recent round was Grant. The last funding was announced in February 2022.
InvVax's investors include National Science Foundation, Sand Hill Angels, TCA Venture Group, Life Science Angels, Seed San Diego.
InvVax is headquartered in Los Angeles, United States.
InvVax is harnessing the human adaptive immune system to fight global infectious disease including pandemic influenza.
InvVax is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"InvVax — Funding & Investors." VCBacked, February 18, 2022, https://www.vcbacked.co/company/invvax. Accessed August 14, 2026.
VCBacked. (2022). InvVax — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/invvax
{{cite web |title=InvVax — Funding & Investors |url=https://www.vcbacked.co/company/invvax |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated